This federal Project Grant award, R01CA273001, was provided by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395). The $402,874 award will fund research at the University of Texas Medical Branch at Galveston (UTMB) to investigate the mechanisms underlying paclitaxel-induced peripheral neuropathy (PIPN), a significant adverse effect experienced by cancer patients receiving paclitaxel infusion. The research aims to determine if the acute over-excitation...
This Cooperative Agreement award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program, provides $818,360 to the University of Southern California to develop new angiotensin AT2 receptor antagonists for the treatment of neuropathic pain. The research aims to identify and optimize a novel lead series of highly potent and safe AT2R antagonists that...
The federal Project Grant award R21CA298918, provided by the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), supports the development and screening of novel flupirtine analogues for the treatment of chemotherapy-induced neuropathic pain (CINP). The $179,403 grant aims to strategically synthesize potent KV7.2/7.3 activators that can effectively relieve CINP without the hepatotoxicity associated with the flupirtine parent compound. Key objectives include (1)...
This $1,511,970 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports the development of selective GPR34 antagonists for the treatment of neuropathic pain. The award aims to identify CNS-active GPR34 hits that can be further developed into novel GPR34 antagonists as potential drug candidates for neuropathic pain. Key products and services include: 1) Synthesis and testing of novel...
This federal Project Grant award for $1,587,553.00 was provided by the National Institute of Neurological Disorders and Stroke under the Drug Use and Addiction Research Programs (CFDA 93.279). The grant is focused on developing novel 5-HT3 receptor antagonists for the treatment of neuropathic pain. The key objectives are to: 1) use computational drug design approaches to identify novel 5-HT3 receptor antagonist chemotypes with potential for central nervous system (CNS) penetration and...
This Project Grant award of $601,091.00 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research at The Ohio State University to investigate the role of the inflammatory molecule S100A9 in mitigating paclitaxel-induced peripheral neuropathy (PIPN). The key objectives are to: (I) characterize the mechanism by which S100A9 contributes to PIPN, focusing on neuro-immune interactions; (II) determine an optimal regimen to pharmacologically inhibit S100A9 and...
The federal Project Grant award R01NS139492, totaling $664,772, was provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) grant program. The award aims to dissect the signaling mechanisms involving the neurotensin receptor 2 (NTSR2) and calcium channels (Cav2.3 and Cav2.2) as a potential non-opioid spinal analgesic approach for the treatment of high-impact chronic pain...
This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to investigate the role of Schwann cell dysfunction and repair signaling in chemotherapy-induced painful peripheral neuropathy (CIPPN). The research will examine the potential of targeting peroxisome proliferator-activated receptor gamma (PPARG) and low-density lipoprotein receptor-related protein 1 (LRP1) signaling in...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $675,107 to Northeastern University to develop novel non-opioid, non-addictive analgesics for treating neuropathic pain. The key objectives are to: 1) Design and synthesize a series of N-arylindole and 2-cycyloalkyllindole analogs as cannabinoid CB1/CB2 receptor agonist-positive...
The federal Project Grant award, R21CA297068, titled "Contribution of Cutaneous Neuro-Immune Interactions to Chemotherapy-Induced Peripheral Neuropathy," is funded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) in the amount of $426,960.00 from September 1, 2024 to November 30, 2026. The award supports research conducted by Wake Forest University Health Sciences to characterize the neuro-immune interactions in the skin of tumor-bearing mice with...